Myriad stock stumbles on potential investor worries over reimbursement, SCOTUS ruling
This article was originally published in Clinica
Executive Summary
An unexpected dip in Myriad Genetics' share price – down 5% to $25.04 – yesterday got analysts guessing about the reasons that could be making the cancer test firm's investors skitterish.